Published in

SpringerOpen, EJNMMI Radiopharmacy and Chemistry, 1(1), 2016

DOI: 10.1186/s41181-016-0008-2

Links

Tools

Export citation

Search in Google Scholar

Alpha-PET with terbium-149: evidence and perspectives for radiotheragnostics

Journal article published in 2016 by Cristina Müller, Ulli Köster, Christiaan Vermeulen, Karl Johnston ORCID, Roger Schibli, Andreas Türler, Nicholas P. van der Meulen
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Green circle
Preprint: archiving allowed
Upload
Green circle
Postprint: archiving allowed
Upload
Green circle
Published version: archiving allowed
Upload
Policy details
Data provided by SHERPA/RoMEO

Abstract

Other ; 149Tb represents a powerful alternative to currently used α-emitters: the relatively short half-life (T1/2 = 4.1 h), low α-energy (3.97 MeV, Iα = 16.7 %), absence of α-emitting daughters and stable coordination via DOTA are favorable features for potential clinical application. In this letter, we wish to highlight the unique characteristics of 149Tb for PET imaging, based on its positron emission (Eβ+mean = 730 keV, Iβ+ = 7.1 %) in addition to it’s a therapeutic value. To this end, a preclinical study with a tumor-bearing mouse is presented. The perspective of alpha-PET makes 149Tb highly appealing for radiotheragnostic applications in future clinical trials.